ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF

Abivax S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026

$87.49−0.64 (-0.73%)

Close on Oct 19, 2026

Abivax S.A. cash flow statement

Annual Quarterly TTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31
Depreciation & Amortization	0.37	0.37	0.28	0.27	0.25	0.27	0.28	0.25	0.37	0.21
Stock-Based Compensation	17	23	13	11	6.33	4.69	4.46	4.35	5.67	5.76
Change in Accounts Payable	9.49	-8.05	8.05	-28	0.98	13	0.17	14	-22	5.20
Operating Cash Flow	-52	-51	-23	-71	-33	-33	-34	-35	-50	-35
Capital Expenditures	-0.11	-0.05	-0.09	0.01	-0.02	-0.04	-0.09	-0.31	-0.22	-0.01
Investing Cash Flow	0.97	0.50	-13	3.28	0.19	1.08	0.56	1.75	12	1.90
Stock Issued	–	–	0	–	–	–	0	–	–	–
Financing Cash Flow	-39	0.07	-40	603	-8.77	-7.84	-5.83	-6.29	19	21
Foreign Exchange Rate Adjustments	-1.21	7.42	-1.31	-7.16	-1.09	-0.70	2.55	-1.94	0.45	1.32
Net Change in Cash	-89	-39	-73	529	-43	-41	-36	-42	-19	-10
Free Cash Flow	-52	-51	-23	-71	-33	-33	-34	-36	-51	-35
Income Taxes Paid	0	0	–	–	0	0	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 5.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 541.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.